228 Chapter 8 28. Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, et al. Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung CancerCDO1, HOXA9, and TAC1 Methylation for the Diagnosis of Lung Cancer. Clinical Cancer Research. 2014;20(7):1856-64. 29. Liu B, Ricarte Filho J, Mallisetty A, Villani C, Kottorou A, Rodgers K, et al. Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer. Clinical Cancer Research. 2020;26(16):4339-48. 30. Ushiku H, Yamashita K, Katoh H, Ema A, Minatani N, Kikuchi M, et al. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma. Dis Esophagus. 2017;30(2):1-9. 31. Marinelli LM, Kisiel JB, Slettedahl SW, Mahoney DW, Lemens MA, Shridhar V, et al. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecol Oncol. 2022;165(3):568-76. 32. Maekawa H, Ito T, Orita H, Kushida T, Sakurada M, Sato K, et al. Analysis of the methylation of CpG islands in the CDO1, TAC1 and CHFR genes in pancreatic ductal cancer. Oncology letters. 2020;19(3):2197-204. 33. Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, et al. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. Epigenetics. 2016;11(12):871-80. 34. Deckers IA, Schouten LJ, Van Neste L, Van Vlodrop IJ, Soetekouw PM, Baldewijns MM, et al. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival OutcomeCDO1 Promoter Methylation and Clear-Cell Renal Cell Cancer. Clinical Cancer Research. 2015;21(15):3492-500. 35. Kojima K, Nakamura T, Ooizumi Y, Igarashi K, Tanaka T, Yokoi K, et al. Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer. PloS one. 2019;14(1):e0211108. 36. Weng J, Kisiel J, Slettedahl S, Mahoney D, Cao X, Foote P, et al. 42/#466 Tissue-specific methylated DNA marker discriminate among endometrial, ovarian, and cervical cancers. International Journal of Gynecologic Cancer. 2022;32(Suppl 3):A44-A5. 37. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nature communications. 2018;9(1):5068. 38. Ibrahim J, Op de Beeck K, Fransen E, Peeters M, Van Camp G. Genome-wide DNA methylation profiling and identification of potential pan-cancer and tumor-specific biomarkers. Mol Oncol. 2022;16(12):2432-47. 39. Cheng THT, Jiang P, Tam JCW, Sun X, Lee W-S, Yu SCY, et al. Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clinical Biochemistry. 2017;50(9):496-501. 40. Romagnoli D, Nardone A, Galardi F, Paoli M, De Luca F, Biagioni C, et al. MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples. Briefings in Bioinformatics. 2023;24(2).
RkJQdWJsaXNoZXIy MjY0ODMw